E. N. Kharlamova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
E. N. Kharlamova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
7 shared publications - Tatiana M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
6 shared publications - Galina Mikhailovna Tarasova
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - Kamila S. Nurbaeva
V.A. Nasonova Research Institute of Rheumatology, Moscow 115522, Russia
4 shared publications - Olga N. Egorova
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - Ju. Ju. Karpenko
State Budgetary Educational Institution of High Professional Education «Voronezh State Medical University n.a. N.N. Burdenko» of the Ministry of Health of the Russian Federation, Department of Hospital Therapy and Endocrinology
2 shared publications
Latest Publications
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Ocular involvement in antineutrophil cytoplasmic antibody-associated vasculitis
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Ocular involvement in antineutrophil cytoplasmic antibody-associated vasculitis
- Open Access
- 28 August 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (4) , 86-95
Granulomatosis with polyangiitis and microscopic polyangiitis: pathogenesis and clinical manifestations
This literature review addresses the epidemiology, genetic markers, pathogenesis, clinical features, and diagnostic approaches of granulomatosis with polyangiitis and microscopic polyangiitis – both antineutrophil cytoplasmic antibody-associated vasculitides. Particular attention is paid to the role of neutrophil activation and the alternative complement pathway in disease development. The review also includes information on avacopan, an orally administered, selective C5a receptor (C5aR1) inhibitor that blocks the C5a complement component signaling pathway.
- 28 August 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (4) , 86-95
Open AccessGranulomatosis with polyangiitis and microscopic polyangiitis: pathogenesis and clinical manifestations
This literature review addresses the epidemiology, genetic markers, pathogenesis, clinical features, and diagnostic approaches of granulomatosis with polyangiitis and microscopic polyangiitis – both antineutrophil cytoplasmic antibody-associated vasculitides. Particular attention is paid to the role of neutrophil activation and the alternative complement pathway in disease development. The review also includes information on avacopan, an orally administered, selective C5a receptor (C5aR1) inhibitor that blocks the C5a complement component signaling pathway.
- Open Access
- 14 December 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (6) , 90-97
The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
Vasculitis associated with antineutrophil cytoplasmic antibodies (AAV) is a potentially dangerous autoimmune disease characterized by necrotizing inflammation of small blood vessels. In the pathogenesis of AAV, both innate and adaptive immunity are closely linked to neutrophil function. The study of the pathogenetic mechanisms of neutrophil activation in AAV may serve as a prerequisite for the development of more accurate and modern methods of laboratory diagnostics as well as new treatment approaches targeting neutrophils. The review presents an analysis of studies addressing the issue of neutrophil activation in AAV.
- 14 December 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (6) , 90-97
Open AccessThe role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
Vasculitis associated with antineutrophil cytoplasmic antibodies (AAV) is a potentially dangerous autoimmune disease characterized by necrotizing inflammation of small blood vessels. In the pathogenesis of AAV, both innate and adaptive immunity are closely linked to neutrophil function. The study of the pathogenetic mechanisms of neutrophil activation in AAV may serve as a prerequisite for the development of more accurate and modern methods of laboratory diagnostics as well as new treatment approaches targeting neutrophils. The review presents an analysis of studies addressing the issue of neutrophil activation in AAV.
- Open Access
- 21 August 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 66-73
Serum calprotectin in vasculitis associated with antineutrophil cytoplasmic antibodies
Antineutrophil cytoplasmic antibody-associated systemic vasculitis (ANCA-SV) is a group of rare and potentially severe systemic diseases. The search for reliable methods to assess ANCA-SV activity remains relevant. Among the indicators of neutrophil activation that have emerged in clinical practice, the level of serum calprotectin (CLP) stands out, which can be a marker for monitoring vasculitis activity and identifying patients at risk of disease relapse. Objective: to determine serum CLP levels in patients with ANCA-SV. Material and methods. The study group comprised 64 patients (37 with granulomatosis with polyangiitis, 11 with eosinophilic granulomatosis with polyangiitis and 16 with microscopic polyangiitis) aged 18 years and older with a confirmed diagnosis of ANCA-SV. The control group consisted of 30 healthy individuals. ANCA-SV activity was determined using the BVAS index; high activity corresponded to a BVAS value of >3. Damage was assessed using the VDI index. Depending on ANCA-SV activity, patients were divided into two groups: high activity group (group 1, n=33) and low activity group (group 2, n=31). In addition to the generally accepted indicators, serum CLP levels were assessed in all patients with ANCA-SV and healthy donors. Results and discussion. Statistically significant differences (pConclusion. Serum CLP concentration is significantly higher in patients with active ANCA-SV and is related to NLR and SII inflammatory indices, so we consider the possibility of using this indicator to assess disease activity.
- 21 August 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 66-73
Open AccessSerum calprotectin in vasculitis associated with antineutrophil cytoplasmic antibodies
Antineutrophil cytoplasmic antibody-associated systemic vasculitis (ANCA-SV) is a group of rare and potentially severe systemic diseases. The search for reliable methods to assess ANCA-SV activity remains relevant. Among the indicators of neutrophil activation that have emerged in clinical practice, the level of serum calprotectin (CLP) stands out, which can be a marker for monitoring vasculitis activity and identifying patients at risk of disease relapse. Objective: to determine serum CLP levels in patients with ANCA-SV. Material and methods. The study group comprised 64 patients (37 with granulomatosis with polyangiitis, 11 with eosinophilic granulomatosis with polyangiitis and 16 with microscopic polyangiitis) aged 18 years and older with a confirmed diagnosis of ANCA-SV. The control group consisted of 30 healthy individuals. ANCA-SV activity was determined using the BVAS index; high activity corresponded to a BVAS value of >3. Damage was assessed using the VDI index. Depending on ANCA-SV activity, patients were divided into two groups: high activity group (group 1, n=33) and low activity group (group 2, n=31). In addition to the generally accepted indicators, serum CLP levels were assessed in all patients with ANCA-SV and healthy donors. Results and discussion. Statistically significant differences (pConclusion. Serum CLP concentration is significantly higher in patients with active ANCA-SV and is related to NLR and SII inflammatory indices, so we consider the possibility of using this indicator to assess disease activity.
- Open Access
- 22 April 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (2) , 7-15
Differential diagnosis of a local form of granulomatosis with polyangiitis: ocular and ear involvement (part 2)
Granulomatosis with polyangiitis (GPA) is a primary vasculitis associated with antineutrophil cytoplasmic antibodies, characterized by necrotizing vasculitis with predominant involvement of small vessels of various localization and necrotizing granulomatous inflammation with multiple clinical manifestations. GPA remains one of the most severe and prognostically unfavorable systemic vasculitis. The second part of the article presents data on the differential diagnosis of the onset of the disease with the ocular and ear involvement, which requires an interdisciplinary approach and interaction between doctors of different specialties. In the refractory course of the local form of GPA, immunosuppressive therapy, including glucocorticoids and rituximab or cyclophosphamide, is advisable.
- 22 April 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (2) , 7-15
Open AccessDifferential diagnosis of a local form of granulomatosis with polyangiitis: ocular and ear involvement (part 2)
Granulomatosis with polyangiitis (GPA) is a primary vasculitis associated with antineutrophil cytoplasmic antibodies, characterized by necrotizing vasculitis with predominant involvement of small vessels of various localization and necrotizing granulomatous inflammation with multiple clinical manifestations. GPA remains one of the most severe and prognostically unfavorable systemic vasculitis. The second part of the article presents data on the differential diagnosis of the onset of the disease with the ocular and ear involvement, which requires an interdisciplinary approach and interaction between doctors of different specialties. In the refractory course of the local form of GPA, immunosuppressive therapy, including glucocorticoids and rituximab or cyclophosphamide, is advisable.
- Open Access
- 22 April 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (2) , 93-99
Thrombosis risk factors in ANCA-associated vasculitis
The article presents a review of current data on arteriovenous thrombosis risk factors in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Thrombotic complications are among the most frequent prognostically unfavorable factors in AAV. In general, patients with AAV are at greater risk of mortality from cardiovascular events compared with the general population and patients with other forms of systemic vasculitis. Understanding the mechanisms of thrombosis, as well as pathogenic factors that cause an increased risk of arterial and venous thrombosis in AAV, can improve the quality of management of these patients. Therefore, the question of the need for primary and secondary prevention of thrombosis in AAV is of great practical importance. The presented data show the need to estimate the probability of thrombosis in patients with AAV, taking into account risk factors, as well as the influence of the disease itself and ongoing therapy. Assessment of the risk of thrombosis (both venous and arterial) is necessary for the timely administration of adequate preventive treatment of thrombotic complications in AAV.
- 22 April 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (2) , 93-99
Open AccessThrombosis risk factors in ANCA-associated vasculitis
The article presents a review of current data on arteriovenous thrombosis risk factors in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Thrombotic complications are among the most frequent prognostically unfavorable factors in AAV. In general, patients with AAV are at greater risk of mortality from cardiovascular events compared with the general population and patients with other forms of systemic vasculitis. Understanding the mechanisms of thrombosis, as well as pathogenic factors that cause an increased risk of arterial and venous thrombosis in AAV, can improve the quality of management of these patients. Therefore, the question of the need for primary and secondary prevention of thrombosis in AAV is of great practical importance. The presented data show the need to estimate the probability of thrombosis in patients with AAV, taking into account risk factors, as well as the influence of the disease itself and ongoing therapy. Assessment of the risk of thrombosis (both venous and arterial) is necessary for the timely administration of adequate preventive treatment of thrombotic complications in AAV.
- Open Access
- 15 February 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (1) , 7-15
Differential diagnosis of a local form of granulomatosis with polyangiitis: nasal cavity and paranasal sinuses lesions (part 1)
Granulomatosis with polyangiitis (GPA) is a primary vasculitis associated with antineutrophil cytoplasmic antibodies, characterized by necrotizing vasculitis with predominant involvement of small vessels of various localizations and necrotizing granulomatous inflammation with multiple clinical manifestations. GPA remains one of the most severe systemic vasculitis with unfavorable prognosis. When analyzing the course of the disease, there are two variants of GPA, local (with lesions of the upper respiratory tract, URT, organs of vision and hearing) and generalized (with lesions of the URT, organs of vision and hearing in combination with the lungs and/or kidneys, gastrointestinal tract, nervous systems, skin involvement).The article discusses the differential diagnosis of the disease with the nasal cavity and paranasal sinuses lesions onset, which requires an interdisciplinary approach and interaction of doctors of different specialties.
- 15 February 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (1) , 7-15
Open AccessDifferential diagnosis of a local form of granulomatosis with polyangiitis: nasal cavity and paranasal sinuses lesions (part 1)
Granulomatosis with polyangiitis (GPA) is a primary vasculitis associated with antineutrophil cytoplasmic antibodies, characterized by necrotizing vasculitis with predominant involvement of small vessels of various localizations and necrotizing granulomatous inflammation with multiple clinical manifestations. GPA remains one of the most severe systemic vasculitis with unfavorable prognosis. When analyzing the course of the disease, there are two variants of GPA, local (with lesions of the upper respiratory tract, URT, organs of vision and hearing) and generalized (with lesions of the URT, organs of vision and hearing in combination with the lungs and/or kidneys, gastrointestinal tract, nervous systems, skin involvement).The article discusses the differential diagnosis of the disease with the nasal cavity and paranasal sinuses lesions onset, which requires an interdisciplinary approach and interaction of doctors of different specialties.
- Open Access
- 17 December 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (6) , 7-11
Microbiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part 2: gout therapy and the gut microbiota
The article presents current data on the effect of drugs for the treatment of gout on the composition and function of the intestinal microbiota. The potential possibilities of pre- and probiotics use for the prevention and complex therapy of gout are discussed, therapeutic effect may be associated with their impact on the uric acid synthesis and intestinal excretion, as well as with anti-inflammatory properties. The need for further research in this area is emphasized.
- 17 December 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (6) , 7-11
Open AccessMicrobiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part 2: gout therapy and the gut microbiota
The article presents current data on the effect of drugs for the treatment of gout on the composition and function of the intestinal microbiota. The potential possibilities of pre- and probiotics use for the prevention and complex therapy of gout are discussed, therapeutic effect may be associated with their impact on the uric acid synthesis and intestinal excretion, as well as with anti-inflammatory properties. The need for further research in this area is emphasized.
- Open Access
- 18 October 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (5) , 7-12
Microbiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part I: the current state of the problem
The gut microbiota plays a key role in metabolism and immune regulation, and imbalance in microbial composition can contribute to various diseases. We present up-to-date data on the role of the gut microbiota in the occurrence of chronic hyperuricemia (HU) and gout, which is associated with the influence of the microbiota on the synthesis of purine-metabolizing enzymes and pro-inflammatory cytokines. It has been shown that the gut microbiota plays an important role in the pathophysiology of gout and can serve as a new target for therapy. Currently, the microbial index of gout is considered as a potential method for early diagnosis of the disease, possibly already at the preclinical stage. The gut microbiota can be a starting point in the study of the pathogenesis of HU and gout. This makes it necessary to assess the pathogenetic relationship between individual specific microorganisms, the microbiota as a whole, and the development of uric acid (UA) metabolism disorders that contribute to the onset of HU and its transformation into gout. It is assumed that this approach will provide a more complete understanding of the gut microbiota participation in the synthesis of UA and its extrarenal excretion, as well as of bacteria and bacterial enzymes that can be used as a probiotic coadjuvant for the treatment and prevention of gout.
- 18 October 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (5) , 7-12
Open AccessMicrobiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part I: the current state of the problem
The gut microbiota plays a key role in metabolism and immune regulation, and imbalance in microbial composition can contribute to various diseases. We present up-to-date data on the role of the gut microbiota in the occurrence of chronic hyperuricemia (HU) and gout, which is associated with the influence of the microbiota on the synthesis of purine-metabolizing enzymes and pro-inflammatory cytokines. It has been shown that the gut microbiota plays an important role in the pathophysiology of gout and can serve as a new target for therapy. Currently, the microbial index of gout is considered as a potential method for early diagnosis of the disease, possibly already at the preclinical stage. The gut microbiota can be a starting point in the study of the pathogenesis of HU and gout. This makes it necessary to assess the pathogenetic relationship between individual specific microorganisms, the microbiota as a whole, and the development of uric acid (UA) metabolism disorders that contribute to the onset of HU and its transformation into gout. It is assumed that this approach will provide a more complete understanding of the gut microbiota participation in the synthesis of UA and its extrarenal excretion, as well as of bacteria and bacterial enzymes that can be used as a probiotic coadjuvant for the treatment and prevention of gout.